START-UP’s monthly update on technology transfer deals—licensing agreements between companies and universities or other research institutions—in in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical equipment & supplies.
Iverson Genetic Diagnostics gets rights to Johns Hopkins' cardiovascular/infertility diagnostics
Iverson Genetic Diagnostics Inc. has licensed exclusive rights to Johns Hopkins University School of Medicine’s molecular diagnostics to...
Create an account to read this article
Already a subscriber?
Months after terminating obesity candidate danuglipron, Pfizer is placing a hefty bet on Metsera and what it calls its highly differentiated incretin/amylin analog candidates.
Plus deals involving Frame Bio/Mercury Bio, Arch Biopartners/Lidpro, Lilly/Remedium, Cadrenal/eXIthera, Vertex/Enlaza and more.
Radiotherapy enhancer JNJ-1900 (NBTXR3) generated a 47% ORR and 78.9% DCR in melanoma patients after multiple prior rounds of treatment. Discussions about development in additional cancers are ongoing with partner J&J.
About four months after GSK paid $1.2bn up front for another FGF21 analog in MASH, Roche looks to buy 89bio, adding Phase III pegozafermin to its growing cardiometabolic pipeline.
India revokes Novartis's patent pertaining to Entresto, upholding the objections of opponents including the Indian Pharmaceutical Alliance on lack of novelty and prior claiming, among others. Novartis decided against participating in the hearings.
In this week's episode: GSK announces US investments during Trump’s UK visit; Lilly thinks twice about UK lab investment; analyzing the rise in China R&D and deals; Regeneron CEO on his company’s ignored blockbusters; and AstraZeneca’s COPD trial failure.
Plus deals involving Frame Bio/Mercury Bio, Arch Biopartners/Lidpro, Lilly/Remedium, Cadrenal/eXIthera, Vertex/Enlaza and more.
